SE402592B - Forfarande for framstellning av 2-alkyl-3-acyl-pyrazolo(1,5-a)pyridiner - Google Patents

Forfarande for framstellning av 2-alkyl-3-acyl-pyrazolo(1,5-a)pyridiner

Info

Publication number
SE402592B
SE402592B SE7304464A SE7304464A SE402592B SE 402592 B SE402592 B SE 402592B SE 7304464 A SE7304464 A SE 7304464A SE 7304464 A SE7304464 A SE 7304464A SE 402592 B SE402592 B SE 402592B
Authority
SE
Sweden
Prior art keywords
pyrazolo
pyridines
acyl
alkyl
procedure
Prior art date
Application number
SE7304464A
Other languages
English (en)
Swedish (sv)
Inventor
T Irikura
M Hayashi
K Koshirae
Y Kudo
J Hatayama
E Hetsugi
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of SE402592B publication Critical patent/SE402592B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE7304464A 1972-03-30 1973-03-29 Forfarande for framstellning av 2-alkyl-3-acyl-pyrazolo(1,5-a)pyridiner SE402592B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP47032033A JPS5229318B2 (it) 1972-03-30 1972-03-30

Publications (1)

Publication Number Publication Date
SE402592B true SE402592B (sv) 1978-07-10

Family

ID=12347544

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7304464A SE402592B (sv) 1972-03-30 1973-03-29 Forfarande for framstellning av 2-alkyl-3-acyl-pyrazolo(1,5-a)pyridiner

Country Status (12)

Country Link
US (1) US3850941A (it)
JP (1) JPS5229318B2 (it)
AR (1) AR197709A1 (it)
BE (1) BE797554A (it)
BR (1) BR7302268D0 (it)
CA (1) CA989843A (it)
DE (1) DE2315801C3 (it)
ES (1) ES413188A1 (it)
FR (1) FR2182914B1 (it)
GB (1) GB1378375A (it)
HU (1) HU167305B (it)
SE (1) SE402592B (it)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
US4097483A (en) * 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
US4237300A (en) * 1975-12-09 1980-12-02 Merck & Co., Inc. Certain 6-substituted-2-pyridinamines
JPS5968553A (ja) * 1982-10-13 1984-04-18 Automob Antipollut & Saf Res Center 燃料タンク内蔵式燃料ポンプ
JPS6072975U (ja) * 1983-10-26 1985-05-22 ヤンマーディーゼル株式会社 燃料ポンプのエア抜き装置
JPH0621066B2 (ja) * 1984-03-14 1994-03-23 杏林製薬株式会社 ３―イソブチリル―２―イソプロピルピラゾロ〔１，５―ａ〕ピリジンの徐放性医薬品組成物
JPS6263520A (ja) * 1985-09-14 1987-03-20 Kyorin Pharmaceut Co Ltd 抗リウマチ剤
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
JPH01153633A (ja) * 1987-12-10 1989-06-15 Kyorin Pharmaceut Co Ltd 経皮吸収製剤
EP0355234A1 (en) * 1988-08-25 1990-02-28 Merrell Dow Pharmaceuticals Inc. Pyrazolopyridine derivatives as antiatherosclerotic and antihypercholesterolemic agents
JPH085790B2 (ja) * 1988-11-11 1996-01-24 杏林製薬株式会社 記憶障害改善薬
JPH0256853U (it) * 1989-10-04 1990-04-24
JPH06166687A (ja) * 1990-07-18 1994-06-14 Senju Pharmaceut Co Ltd ピラゾロ〔１，５−ａ〕ピリジン化合物、その製造法および用途
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
EP1545519B1 (en) 2002-08-19 2011-03-23 Pfizer Inc. Combination therapy for hyperproliferative diseases
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
CN1812983A (zh) 2003-05-30 2006-08-02 兰贝克赛实验室有限公司 取代的吡咯衍生物及其作为hmg－co抑制剂的用途
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
DE602004031356D1 (de) 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
SG166829A1 (en) 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7585875B2 (en) 2006-06-06 2009-09-08 Avigen, Inc. Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
EP2131841B1 (en) 2007-01-30 2012-08-01 Avigen, Inc. Methods for treating acute pain
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US7536799B2 (en) * 2007-06-07 2009-05-26 Keson Industries Chalk line apparatus with strategically located chalk fill opening
US20100226881A1 (en) * 2007-07-11 2010-09-09 Auckland Uniservices Limited PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY
US20120121540A1 (en) * 2007-08-10 2012-05-17 Franz Ulrich Schmitz Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections
WO2009022740A1 (ja) 2007-08-15 2009-02-19 Kyorin Pharmaceutical Co., Ltd. イブジラストを有効成分とする脳動脈瘤の予防、形成抑制又は治療剤
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010005520A2 (en) * 2008-06-30 2010-01-14 Concert Pharmaceuticals, Inc. 2-alkyl-3-acylpyrazolo[1,5-a]pyridine derivatives
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2320907A4 (en) * 2008-08-05 2012-09-05 Merck Sharp & Dohme THERAPEUTIC COMPOUNDS
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
CN102655866B (zh) 2009-11-13 2013-11-13 东丽株式会社 糖尿病的治疗或预防药
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
ES2395801B1 (es) 2011-06-23 2014-06-06 María Carmen PARDINA PALLEJÀ "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"
CN102617579A (zh) * 2012-03-28 2012-08-01 黑龙江大学 一种异丁司特的制备方法
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN108033959A (zh) * 2018-01-29 2018-05-15 山东省药学科学院 一种异丁司特的化学合成方法
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Also Published As

Publication number Publication date
ES413188A1 (es) 1976-01-16
JPS4897898A (it) 1973-12-13
BE797554A (fr) 1973-07-16
AU5376173A (en) 1974-09-26
CA989843A (en) 1976-05-25
DE2315801A1 (de) 1973-10-11
HU167305B (it) 1975-09-27
JPS5229318B2 (it) 1977-08-01
DE2315801B2 (de) 1978-06-22
AR197709A1 (es) 1974-04-30
FR2182914B1 (it) 1976-05-14
DE2315801C3 (de) 1979-02-22
GB1378375A (en) 1974-12-27
US3850941A (en) 1974-11-26
BR7302268D0 (pt) 1974-08-29
FR2182914A1 (it) 1973-12-14

Similar Documents

Publication Publication Date Title
SE432767B (sv) Forfarande for framstellning av oxazolo-(5,4-b)-pyridiner
SE407579B (sv) Forfarande for framstellning av n-fosfonometylglycin
AR197709A1 (es) Un procedimiento para la preparacion de un derivado de 2-aquil-3-acil-pirazolo(1,5-a) piridina
SE390819B (sv) Analogiforfarande for framstellning av piperazinyl-propyl-1,2,4-triazolinderivat
NO140731C (no) Fremgangsmaate for fremstilling av dimetyleter
SE395149B (sv) Forfarande for framstellning av dibenso-tiepinylpiperazinderivat
SE381047B (sv) Forfarande for framstellning av 3-substituerade 1,2-bensisoxazolderivat
SE401676B (sv) Forfarande for framstellning av dibensofuranderivat
SE382053B (sv) Forfarande for framstellning av bifenylylalkanoylaminopyridiner
SE383151B (sv) Forfarande for framstellning av 1-hydroxi-2-pyridoner
RO79057A (ro) Procedeu pentru prepararea unor imidazoli-(4,5-b)-piridine
AR192347A1 (es) Procedimiento para la preparacion de 3-amino-imidazo(1,5-a)piridinas
SE402009B (sv) Forfarande for framstellning av 9-desoxi-prosta-5,9,(10),13-triensyraderivat
SE400768B (sv) Forfarande for framstellning av 2-fenyl-6-sulfamoyl-7-klor-1,2,3,4-tetrahydro-4-kinazolinon
FI56830B (fi) Foerfarande foer framstaellning av asparaginylgrupper innehaollande biologiskt aktiva polypeptider
SE380272B (sv) Forfarande for framstellning av n-fosfonmetylglycin
SE393111B (sv) Forfarande for framstellning av d-2-halogen-6-metyl-8-substituerad - ergolin
SE393808B (sv) Forfarande for framstellning av isomaltit
SE415355B (sv) Forfarande for framstellning av fosfonotioureider
FI52735C (fi) Menetelmä uusien pregnadieeni-21-happojohdannaisten valmistamiseksi.
BG20583A3 (bg) Метод за получаване на 2,6-диамино-дихидропиридини
SE399557B (sv) Forfarande for framstellning av tiantren-, tioxanten- och fenoxatiinderivat
SE400086B (sv) Forfarande for framstellning av acylerade n(6)- aralkyl-adenosin-derivat
SE391717B (sv) Forfarande for framstellning av 4-aryl-5-aminoalkyl-4-oxazolin-2-oner
SE380804B (sv) Anologiforfarande for framstellning av s-triazolo (1,5-a) (1,4)